Jointly developed by China and Cuba, a new kind of vaccine used to treat non-small-cell lung cancer (NSCLC) has obtained the approval of China's State Food and Drug Administration. It is about to conduct clinical tests at the Chinese Academy of Medical Sciences (CAMS).
The news was released at the China-Cuba Biopharmaceutical Achievement Analysis and Prospect Conference, held by the Biotech Pharmaceuticals Co Ltd.
Dr. Agustín Lage Dávila is the director of the Center of Molecular Immunology and is a renowned biotechnologist in Cuba. He said, "After diagnosis, the development of the tumor will usually disappear and recur with therapy progress."
Dr. Lage said Cimavax, the new vaccine that was jointly developed by Cuba and Biotech, is a conjugated vaccine that recombines the epidermal growth factor (EGF). As a therapeutic vaccine, it directs the EGF required by tumor expansion and prevents the further proliferation of tumor tissues. It thereby keeps the tumor at a stable level and transforms the cancer into a chronic disease, which greatly extends the survival time of the patient.
The clinical trial of this therapeutic vaccine has been conducted in Cuba with local drug registration. Meanwhile, many countries and regions in Europe and Asia have launched the registration trials of the vaccine and have gained positive preliminary results. At present, the vaccine is being converted into product for China.
The Cancer Hospital of CAMS is the partner of the Phase I clinical trial of the project. Vice-president professor, Shi Yuankai, confirmed that the new vaccine will first enter the Phase I clinical trial in the hospital starting in March. Dr. Lage predicted that after two years of clinical trials, the new anticancer vaccine will be put into the market.
As the largest project of the China-Cuba biological cooperation, Biotech has acquired spectacular results in the field of biopharmaceutical anticancer. During its development in the past decade, Biotech has made remarkable achievements in tumor research and treatment and created the first domestic antibody humanization technology platform at a world leading level.
The company has also designed and constructed China's first full-automatic and large-scale mammalian cell culture production line, and researched and developed Nimotuzomab - the first humanized monoclonal antibody of gene recombination for malignant tumor treatment.
Edited by Chen Zhilin and Rakhee M